- Home
- GTN vs ZURA Comparison
GTN vs ZURA Comparison
Compare GTN & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTN | ZURA |
|---|---|---|
| Founded | 1897 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 452.2M | 435.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GTN | ZURA |
|---|---|---|
| Price | $5.04 | $6.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $8.50 | ★ $11.78 |
| AVG Volume (30 Days) | ★ 1.5M | 487.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.44 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.13 | $0.99 |
| 52 Week High | $6.31 | $7.19 |
Technical Indicators
Market Signals| Indicator | GTN | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 61.36 |
| Support Level | $4.42 | $5.62 |
| Resistance Level | $5.35 | N/A |
| Average True Range (ATR) | 0.40 | 0.49 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 36.59 | 78.99 |
Price Performance
Historical ComparisonAbout GTN Gray Television Inc.
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.